Abstract
Purpose: Despite advances in immunosuppressive therapy, T cell mediated rejection continues to be a significant source of morbidity and mortality in heart transplant patients past the first year. T cell antigen receptor (TCR) signaling is the essential element in these alloresponses against donor MHC and non-MHC antigens. Yet there is no therapy to specifically target this process. Dasatinib, an oral kinase inhibitor used for chronic myeloid leukemia, is exquisitely specific for Abl and Src family kinases (SFK), which are critical for the first step of T cell activation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
